Sodium borate

Identification

Name
Sodium borate
Accession Number
DB14505  (DBSALT002513)
Type
Small Molecule
Groups
Approved, Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • Borax
  • Sodium borate anhydrous
Product Ingredients
IngredientUNIICASInChI Key
Sodium borate decahydrate91MBZ8H3QO1303-96-4CDMADVZSLOHIFP-UHFFFAOYSA-N
Active Moieties
NameKindUNIICASInChI Key
Borate ionionic44OAE30D2212258-53-6GDTSJMKGXGJFGQ-UHFFFAOYSA-N
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sodium BoratePowderTopicalLab Valmo EnregistrÉ, Division Of Technilab Inc.1979-12-311999-09-17Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Calcemin AdvanceSodium borate decahydrate (2.45 mg/1) + Calcium carbonate (500 mg/1) + Magnesium oxide (40 mg/1) + Previtamin D(3) (3 mg/1) + Zinc oxide (7.5 mg/1)Tablet, film coatedOralBayer Healthcare Llc.2016-04-01Not applicableUs
Collyre Hygienique SokerSodium borate (1.89 mg) + Boric acid (11.1 mg)LiquidOphthalmicProduits Francais Labs Inc.1978-12-311997-05-30Canada
Eye EzeSodium borate (.18 %) + Boric acid (1.11 %)LiquidOphthalmicPharmavite Laboratories (1987) Inc.1958-12-312006-07-27Canada
GlycothymolineSodium borate (20 mg) + Sodium benzoate (20 mg)LiquidTopicalGlendale Agencies1951-12-311996-11-29Canada
Ma Ying Long HemorrhoidalSodium borate decahydrate (0.2 g/10g) + Amber (0.1 g/10g) + Borneol (0.2 g/10g) + Bos taurus gallstone (0.1 g/10g) + Moschus berezovskii musk sac resin (0.15 g/10g) + Pearl (hyriopsis cumingii) (0.25 g/10g) + Zinc carbonate (0.65 g/10g)OintmentTopicalTrifecta Pharmaceuticals Usa, Llc.2016-01-14Not applicableUs
Miel RosadaSodium borate decahydrate (0.1 mg/1mL) + Glycerin (0.4 mg/1mL)SolutionTopicalDannso corp./d.b.a. Essential Products2015-01-01Not applicableUs
Occu-cal DropsSodium borate (1.9 mg) + Boric acid (11.16 mg) + Phenylephrine hydrochloride (.2 mg)Solution / dropsOphthalmicProduits Francais Labs Inc.1981-12-311997-05-30Canada
Occu-cal LotionSodium borate (1.896 mg) + Boric acid (11.1 mg) + Phenylephrine hydrochloride (.01 mg)LotionOphthalmicProduits Francais Labs Inc.1981-12-311997-05-30Canada
Sel De PerouSodium borate (40 mg) + Sodium carbonate (960 mg)PowderTopicalProduits Francais Labs Inc.1930-12-311997-05-30Canada
Thunas Eye DropsSodium borate (1.9 mg) + Boric acid (11.16 mg)Solution / dropsOphthalmicThuna Herbal Remedies Ltd.1979-12-312002-10-16Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Ma Ying Long HemorrhoidalSodium borate decahydrate (0.2 g/10g) + Amber (0.1 g/10g) + Borneol (0.2 g/10g) + Bos taurus gallstone (0.1 g/10g) + Moschus berezovskii musk sac resin (0.15 g/10g) + Pearl (hyriopsis cumingii) (0.25 g/10g) + Zinc carbonate (0.65 g/10g)OintmentTopicalTrifecta Pharmaceuticals Usa, Llc.2016-01-14Not applicableUs
Categories
UNII
8191EN8ZMD
CAS number
1330-43-4
Weight
Average: 201.219
Monoisotopic: 201.981163568
Chemical Formula
B4Na2O7
InChI Key
UQGFMSUEHSUPRD-UHFFFAOYSA-N
InChI
InChI=1S/B4O7.2Na/c5-1-7-3-9-2(6)10-4(8-1)11-3;;/q-2;2*+1
IUPAC Name
disodium bicyclo[3.3.1]tetraboroxane-3,7-bis(olate)
SMILES
[Na+].[Na+].[O-]B1OB2OB([O-])OB(O1)O2

Pharmacology

Indication

No FDA- or EMA-approved therapeutic indications on its own.

Pharmacodynamics

Boric acid exhibits minimal bacteriostatic and antifungal activities 4. Boric acid is likely to mediate antifungal actions at high concentrations over prolonged exposures 3.

Mechanism of action

Information regarding the mechanism of action of boric acid in mediating its antibacterial or antifungal actions is limited. Boric acid inhibits biofilm formation and hyphal transformation of Candida albicans, which are critical virulence factors 3. In addition, arrest of fungal growth was observed with the treatment of boric acid 3.

Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Boric acid is well absorbed from the gastrointestinal tract, open wounds, and serous cavities but displays limited absorption in intact skin 4. Following intraperitoneal injection in mice, the peak concentration was reached in about 1.0-1.5 hr in the brain whereas the value was 0.5 hr in other tissues 4.

Volume of distribution

Volume of distribution ranges from 0.17 to 0.5 L/kg in humans, where large amounts of boric acid are localized in brain, liver, and kidney 4.

Protein binding

No protein binding reported.

Metabolism

No metabolic pathways reported.

Route of elimination

Regardless the route of administration, boric acid predominantly undergoes rapid renal excretion of >90% of total administered dose as unchanged form. Small amounts are also excreted into sweat, saliva, and feces. Following administration as ointment, urinary excretion of boric acid accounted for only 1% of the administered dose 4.

Half life

According to human cases of poisoning, the elimination half-life of boric acid ranges from 13 to 24 hours 2,4.

Clearance

A case report of acute boric acid poisoning following oral ingestion of 21 g of boric acid presents the total body clearance of 0.99 L/h before hemodialysis 2.

Toxicity

Acute oral LD50 is 2660 mg/kg in rat MSDS. Individuals are likely to be exposed to boric acid from industrial manufacturing or processing. Local tissue injury from boric acid exposure is likely due to caustic effects. Systemic effects from boric acid poisoning usually occur from multiple exposures over a period of days and involve gastrointestinal, dermal, CNS, and renal manifestations. Gastrointestinal toxicity include persistent nausea, vomiting, diarrhea, epigastric pain, hematemesis, and blue-green discoloration of the feces and vomit 4. Following the onset of GI symptoms, a characteristic intense generalized erythroderma follows 4. Management of mild to moderate toxicity should be supportive. In case of severe toxicity, dialysis may be required in addition to supportive treatment.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
  1. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME: Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011 Aug;20(8):1245-55. doi: 10.1089/jwh.2010.2708. Epub 2011 Jul 20. [PubMed:21774671]
  2. Teshima D, Morishita K, Ueda Y, Futagami K, Higuchi S, Komoda T, Nanishi F, Taniyama T, Yoshitake J, Aoyama T: Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. J Pharmacobiodyn. 1992 Jun;15(6):287-94. [PubMed:1432568]
  3. De Seta F, Schmidt M, Vu B, Essmann M, Larsen B: Antifungal mechanisms supporting boric acid therapy of Candida vaginitis. J Antimicrob Chemother. 2009 Feb;63(2):325-36. doi: 10.1093/jac/dkn486. Epub 2008 Dec 4. [PubMed:19059942]
  4. BORIC ACID - National Library of Medicine HSDB Database- Toxnet - NIH [Link]
  5. Boric Acid - National Toxicology Program - NIH [Link]
External Links
ChemSpider
8395345
Wikipedia
Borax
ATC Codes
S01AX07 — Sodium borate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedNot AvailableCorneal Staining1
4CompletedTreatmentEndocrine ophthalmopathy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
LiquidOphthalmic
LiquidTopical
OintmentTopical
SolutionTopical
LotionOphthalmic
PowderTopical
PowderTopical
Solution / dropsOphthalmic
JellyVaginal
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP4.68ChemAxon
pKa (Strongest Acidic)8.35ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area92.27 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity9.64 m3·mol-1ChemAxon
Polarizability11.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on July 11, 2018 15:16 / Updated on March 01, 2020 23:54

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates